Drug intelligence / Profile preview

SBX-2011

Development stage: Preclinical
Lead developer: Stramsen Biotech

Overview

SBX-2011 is a plant-based drug candidate being developed by Stramsen Biotech. It is specifically designed for the treatment of kidney infections and the dissolution or fragmentation of gallstones. As part of Stramsen Biotech's broader pipeline of botanical therapeutics, SBX-2011 aims to provide a natural alternative to traditional pharmaceuticals, focusing on an improved safety profile and reduced side effects. While the specific active botanical ingredients and molecular targets have not been publicly disclosed, the candidate is positioned as a therapeutic intervention for renal and biliary conditions.

Beyond the preview

Go deeper on SBX-2011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBX-2011.

Explore the full profile